Fundació Lluita contra la Sida, Infectious Disease Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Universitat Autònoma de Barcelona, Bellaterra, Spain.
Drugs. 2020 Jun;80(9):859-868. doi: 10.1007/s40265-020-01322-y.
Therapeutic approaches towards a functional cure or eradication of HIV have gained renewed momentum upon encouraging data emerging from studies in SIV monkey models and recent results from human clinical studies. However, a multitude of questions remain to be addressed, including how to deal with the latent viral reservoir, how to boost the host immune response to the virus and what the hurdles are to reach relevant viral compartments in the body. Advances have been made especially with regard to identifying agents that can reactivate the latent virus in vivo and boost the cellular and humoral immunity, but it remains largely unclear whether any of these strategies can awaken a sufficiently large fraction of the viral reservoir and whether the boosted immunity can prevent rapid viral replication once antiretroviral treatments are stopped.
在 SIV 猴模型研究和最近的人类临床研究结果中出现令人鼓舞的数据后,针对 HIV 的功能性治愈或根除的治疗方法再次受到关注。然而,仍有许多问题亟待解决,包括如何处理潜伏的病毒库,如何增强宿主对病毒的免疫反应,以及达到体内相关病毒隔室的障碍是什么。在确定可以在体内重新激活潜伏病毒并增强细胞和体液免疫的药物方面已经取得了进展,但尚不清楚这些策略中的任何一种是否可以唤醒足够大比例的病毒库,以及增强的免疫是否可以阻止一旦停止抗逆转录病毒治疗后病毒的快速复制。